Question index / 25 entries
BPC-157 TB-500 FAQ
The full question inventory, answered off the published record — definitional, mechanistic, dosing, safety, and regulatory, each answer posted as a position with its source.
Definitions and overview
What is the Wolverine peptide blend?
The Wolverine peptide blend is a research-community name for a two-peptide pairing of BPC-157 and TB-500, marketed and discussed as a tissue-repair "stack" [1][3]. It is not a single chemical entity or an approved product, and it has no validated combination dose or controlled human trial [8].
What is BPC-157 and TB-500?
BPC-157 is a synthetic 15-amino-acid pentadecapeptide (GEPPPGKPADDAGLV) derived from a human gastric-juice protein, the cytoprotective and angiogenic component [1][2]. TB-500 is a synthetic Ac-LKKTETQ heptapeptide from the actin-binding region of Thymosin Beta-4, the cytoskeletal cell-migration component [3][7].
What is the BPC-157 and TB-500 blend used for in research?
In research, the constituents are studied for tissue repair — BPC-157 in tendon, gut, and ischemia models [1][2], and Thymosin Beta-4 in wound, cardiac, and migration models [4]. The blend itself has no validated research protocol; no peer-reviewed combination study defines a dose, ratio, or endpoint [8].
Mechanism and comparison
How does TB-500 work (actin / Thymosin Beta-4)?
TB-500's Ac-LKKTETQ motif binds monomeric G-actin 1:1, and crystallography showed Thymosin Beta-4 sequesters the actin monomer by capping both ends, regulating the cytoskeletal dynamics behind cell migration [3]. Most efficacy data attributed to "TB-500" used full-length Thymosin Beta-4, not the fragment [4].
How does BPC-157 work compared to TB-500?
BPC-157 acts extracellularly and vascularly — up-regulating VEGFR2 and activating Akt-eNOS to drive angiogenesis and cytoprotection [2]. TB-500 acts intracellularly on the cytoskeleton, sequestering G-actin to regulate migration [3]. Different, complementary pathways — the stated basis for pairing them [1][3].
What is the difference between BPC-157 and TB-500?
BPC-157 (~1419.5 Da) is a gastric-juice-derived pentadecapeptide that signals angiogenesis and cytoprotection [1][2]; TB-500 (~889.0 Da) is a Thymosin-Beta-4 fragment that regulates actin and cell migration [3]. They differ in size, origin, and mechanism, and most TB-500 data are from the full-length protein [4][7].
Do BPC-157 and TB-500 promote angiogenesis (new blood vessels)?
Yes, by distinct routes. BPC-157 up-regulates VEGFR2 and activates VEGFR2-Akt-eNOS, raising vessel density and blood-flow recovery in ischemia models [2]. Thymosin Beta-4 promotes endothelial migration and angiogenesis, with VEGF/HIF-1alpha reported for the full-length protein [4].
Dosage and administration
What is the half-life of BPC-157 and TB-500?
No validated human half-life exists for either constituent or the blend. BPC-157's elimination half-life was under 30 minutes in a rat/dog study; human intravenous Thymosin Beta-4 showed dose-proportional pharmacokinetics with half-life rising at higher doses [5][6], but the TB-500 heptapeptide has no established half-life.
How do you reconstitute a BPC-157 / TB-500 blend (10mg)?
Both peptides are supplied lyophilized and reconstituted in bacteriostatic or sterile water for research handling, then refrigerated. This site does not provide volumes or instructions; product identity, purity, and the actual BPC-157:TB-500 ratio in unregulated material are not guaranteed.
How often should you inject BPC-157 and TB-500?
There is no validated injection frequency for the blend. Rodent efficacy studies used model-specific intraperitoneal schedules [1][3]; human data are single-agent intravenous Thymosin Beta-4 [5][6]. Community frequency protocols are not derived from controlled trials.
How do you cycle BPC-157 and TB-500?
No controlled human trial defines a cycle. "Loading then maintenance" cycling is a community convention without a controlled-trial basis [8], and the constituent studies used fixed animal schedules, not translatable human cycles.
Safety
What are the side effects of BPC-157 and TB-500?
A 2025 systematic review of BPC-157 found "no clinical safety data" from controlled human trials [8], and there is no combination safety dataset. Human safety data exist only for full-length Thymosin Beta-4, which was well tolerated to 1260 mg intravenously with no serious adverse events in Phase 1 [5][6]. That does not establish the safety of the TB-500 fragment, the blend, or research-community routes.
Does TB-500 cause cancer or promote tumor growth?
This is a theoretical safety signal, not a demonstrated human effect. Thymosin Beta-4 is overexpressed in several cancers and implicated in metastasis and tumor angiogenesis, so the same pro-migratory, pro-angiogenic properties that aid repair could in principle support tumor progression [4] — a concern that compounds when two pro-repair peptides are combined. No human study has measured this risk for TB-500 or the blend.
Is the 'Wolverine' synergy claim actually proven?
No. The synergy claim is an extrapolation from each peptide's separate, largely non-overlapping mechanism [1][3]. No controlled combination study defines a synergistic dose, ratio, or endpoint, and a 2025 BPC-157 systematic review makes no mention of TB-500 or combination use [8].
Community and regulatory
BPC-157 TB-500 reddit
Reddit and forum threads on BPC-157 TB-500 mostly trade anecdotes and community "loading" protocols, which this site does not reproduce as guidance. The published record is narrower than the forum consensus: constituent findings are largely preclinical, the "TB-500" human data are for full-length Thymosin Beta-4 [5][6], and no controlled combination trial exists [8]. Where forum claims and the literature diverge, this terminal posts the literature.
Is Wolverine legal?
Neither component is an FDA-approved drug, and both are currently 503A Category 2 bulk substances, so compounding-pharmacy access is restricted today [11][12]. Both are on a scheduled July 23-24, 2026 FDA advisory-committee agenda for evaluation [13], and both are WADA-prohibited [14]. See the Wolverine legal status page; this is general information, not legal advice.
Can you get BPC-157 from a compounding pharmacy?
Not through routine 503A compounding while its current status stands. BPC-157 is a 503A Category 2 bulk substance, which FDA does not cover under the enforcement-discretion policy that applies to Category 1 [11][12]. Lawful compounded access generally requires a licensed-prescriber evaluation, a valid prescription, and an ingredient eligible under the 503A/503B rules [12].
What is the FDA 503A status of Wolverine?
Both components are 503A Category 2 — bulk drug substances FDA identified as possibly presenting significant safety risks, effective the September 29, 2023 list update [11]. Both BPC-157 and TB-500 are on the July 23-24, 2026 PCAC agenda as candidates being considered for the 503A bulks list, a scheduled evaluation rather than a change in current status [13].